Bayless Integrated Healthcare, located in downtown Phoenix, Arizona, was selected by AstraZeneca for the Phase 3 clinical trial investigating the efficacy of AZD1222, the COVID-19 vaccine originally developed at University of Oxford. Targeting 1, 500 participants, some of whom will come from the health provider’s pool of approximately 30,000 patients. The actual study is being managed by CCT Research. The study team will monitor the participants for two years after the experimental inoculation. The study is offered in both English and Spanish.
This is one of the leading vaccine candidates developed by Oxford University’s Jenner Institute, (ChAdOx1 nCoV-19). Made from a weakened version of a common cold virus (adenovirus), the candidate, which triggers infections in chimpanzees, was genetically modified so that it can’t grow in humans. The UK-based scientists added genetic material used to make proteins from COVID-19 known as the Spike glycoprotein (S), typically located on the surface of the pathogen and that serves as an instrumental element associated with the infection of the virus. That’s because the pathogen uses its spike protein to bind to ACE2 receptor...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).